On Mar. 26, 2009, Roche completed its acquisition of Genentech for $46.8 billion pursuant to a short-form merger in which Genentech became a wholly-owned member of the Roche Group.

Roche agreed to acquire the 44 percent of shares in the U.S. firm it did not already own for $95 each, ending a long pursuit of the U.S. biotech group and its lucrative cancer drugs.